---
title: "Drug evidence library"
description: "Source-traceable formulary evidence on 40 drug and indication records, organized by dossier section and quoted from the published sources."
canonical: "https://www.evicenter.com/drugs"
---

# Drug evidence library

- [4D-150: Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration)
- [Anaphylm (dibutepinephrine, AQST-109): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis)
- [Aqneursa (levacetylleucine, IB1001): Ataxia-telangiectasia](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia)
- [Atebrioz (zilurgisertib, INCB000928): Fibrodysplasia ossificans progressiva](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva)
- [AXPAXLI (axitinib intravitreal implant, OTX-TKI): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration)
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures)
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor)
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis)
- [BIM-IOL System: Open-angle glaucoma or ocular hypertension](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension)
- [Cytisinicline: Smoking cessation](https://www.evicenter.com/drugs/cytisinicline--smoking-cessation)
- [Deramiocel (CAP-1002): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy)
- [Dersimelagon (MT-7117): Erythropoietic protoporphyria or X-linked protoporphyria](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria)
- [Duravyu (vorolanib intravitreal insert, EYP-1901): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration)
- [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency)
- [Emiltatug ledadotin (Emi-Le, XMT-1660): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation)
- [Hibsago (bepirovirsen, GSK3228836): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis)
- [Hovilpri (pritelivir, AIC316): Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults](https://www.evicenter.com/drugs/hovilpri--refractory-mucocutaneous-herpes-simplex-virus-infection-in-immunocompromised-adults)
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients)
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis)
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer)
- [Juvmo (tavapadon, CVL-751): Parkinson's disease](https://www.evicenter.com/drugs/juvmo--parkinson-s-disease)
- [LB-102: Schizophrenia](https://www.evicenter.com/drugs/lb-102--schizophrenia)
- [Lirafugratinib (Lyrfigtu, RLY-4008): Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma)
- [Lonvoguran ziclumeran (lonvo-z, NTLA-2002): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration)
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis)
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations)
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies)
- [RP-A501 (AAV9.LAMP2B): Danon disease](https://www.evicenter.com/drugs/rp-a501--danon-disease)
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis)
- [SKY-0515: Huntington's disease](https://www.evicenter.com/drugs/sky-0515--huntington-s-disease)
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency)
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1)
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma)
- [Tovecimig (CTX-009, ABL001): Second-line advanced biliary tract cancer](https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer)
- [Tovorafenib (DAY101, TAK-580): RAF-altered pediatric low-grade glioma requiring first-line systemic therapy](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy)
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor)
- [Zanzalintinib (XL092): Metastatic colorectal cancer](https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer)
- [Zeleciment rostudirsen (z-rostudirsen, DYNE-251): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy)
- [Zipalertinib (CLN-081, TAS6417): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer)